Fig. 9From: An international comparative analysis of public reimbursement of orphan drugs in Canadian provinces compared to European countriesMedian time (months) between Health Canada approval and public reimbursement by province. AB, Alberta; BC, British Columbia; MB, Manitoba; NB, New Brunswick; NL, Newfoundland; NS, Nova Scotia; ON, Ontario; PE, Prince Edward Island; QC, Quebec; SK, SaskatchewanBack to article page